戻る Agenda
DIAmond Session 1: What Do Patients Want for Clinical Trials and Clinical Research? What Should Stakeholders Do?
Session Chair(s)
Naomi Sakurai
President, CSR-Project, NPO, Japan
Yoshikata Furuya, MSC
Manager, General Affairs Division, Sankeien Hoshoukai Foundation, Japan
Patient and Public Involvement (PPI) in drug developments is increasingly attracting interest in Japan. DIA has organized sessions on PPI at the annual meetings over the past few years to share the concept of PPI and status of PPI in each phase of drug development in Japan and global. In this DIAmond session, leaders of PPI in clinical trials and clinical research will share the latest outcomes and discuss what stakeholders should do to promote PPI in Japan.
Speaker(s)
Yasuhiro Fujiwara, MD, PHD
Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Agnès Saint-Raymond, DrMed
Head of Division International Affairs, European Medicines Agency, Netherlands
Patients’ expectations in Clinical Trials
Kyoko Imamura, MD, PHD
Professor, Social Cooperation Program of IT Healthcare, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Japan
Promoting Patient and Public Involvement in Japan
Takayuki Imaeda, MPHARM, MS
Head of Regulatory Sciences, Pfizer R&D Japan, Japan
Patient and Public Involvement (PPI) in drug developments at a pharmaceutical company’s perspective